本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688016 证券简称：心脉医疗 一、 主要财务数据 (一) 主要会计数据和财务指标 单位：元 币种：人民币 (二) 非经常性损益项目和金额 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假 记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第一季度财务报表是否经审计 □是 √否 √适用 □不适用 单位:元 币种:人民币 对公司将《公开发行证券的公司信息披露解释性公告第1号——非经常性损益》未列举的项目认定为非 经常性损益项目且金额重大的，以及将《公开发行证券的公司信息披露解释性公告第1号——非经常性 损益》中列举的非经常性损益项目界定为经常性损益的项目，应说明原因。 □适用 √不适用 (三) 主要会计数据、财务指标发生变动的情况、原因 √适用 □ ...

上海微创心脉医疗科技（集团）股份有限公司 舆情管理制度 上海微创心脉医疗科技（集团） 股份有限公司 舆情管理制度 二零二五年四月 1 上海微创心脉医疗科技（集团）股份有限公司 舆情管理制度 上海微创心脉医疗科技(集团)股份有限公司 舆情管理制度 第一章 总则 （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品种交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变动 的负面舆情； （二）一般舆情：指除重大舆情之外的其他舆情。 第二章 舆情管理的组织体系和工作职责 第一条 为提高上海微创心脉医疗科技（集团）股份有限公司（以下简称"公 司"）应对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类 舆情对公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法 权益，根据相关法律法规、规范性文件及《上海微创心脉医疗科 ...

Financial Performance - The company's operating revenue for Q1 2025 was CNY 332,189,385.86, a decrease of 7.23% compared to CNY 358,081,405.15 in the same period last year[4] - Net profit attributable to shareholders was CNY 129,636,898.33, down 29.66% from CNY 184,296,095.55 year-on-year[4] - Basic and diluted earnings per share decreased by 30.00% to CNY 1.05 from CNY 1.50 in the previous year[4] - The company's retained earnings rose to ¥1,214,597,510.58 in Q1 2025, up from ¥1,084,960,612.25 in Q1 2024[17] - The company reported a total comprehensive income of ¥124,733,344.22 in Q1 2025, down from ¥182,831,010.57 in Q1 2024[20] Cash Flow - The net cash flow from operating activities decreased by 81.11%, amounting to CNY 40,027,784.30 compared to CNY 211,948,663.78 in the previous year[4] - Cash inflow from operating activities in Q1 2025 was ¥190,732,776.15, a decline of 52.9% from ¥405,086,857.23 in Q1 2024[20] - The net cash flow from operating activities was $40,027,784.30, a significant decrease from $211,948,663.78 in the previous period, reflecting a decline of approximately 81%[21] - The net increase in cash and cash equivalents was -$1,080,353,621.70, an improvement from -$1,493,736,045.88, indicating a reduction in cash outflow of approximately 27.7%[21] - The ending balance of cash and cash equivalents was $978,477,623.44, down from $1,459,364,476.35, representing a decrease of about 33%[21] Assets and Liabilities - The total assets increased by 4.04% to CNY 4,464,876,823.41 from CNY 4,291,597,451.31 at the end of the previous year[5] - The company's cash and cash equivalents decreased to RMB 1,085,676,371.90 from RMB 2,170,604,749.23, representing a decline of about 50%[14] - Accounts receivable increased significantly to RMB 355,333,176.48 from RMB 209,761,864.13, marking a rise of approximately 69.5%[14] - The total current liabilities rose to RMB 458,518,305.05 from RMB 339,038,781.50, indicating an increase of around 35.3%[16] - The total liabilities of the company reached RMB 580,321,010.96, up from RMB 469,125,424.12, which is an increase of about 23.7%[16] Research and Development - Research and development expenses totaled CNY 29,051,147.32, a reduction of 38.37% from CNY 47,137,794.16, representing 8.75% of operating revenue[5] - Research and development expenses decreased to ¥15,941,366.59 in Q1 2025, down 31.0% from ¥23,190,117.20 in Q1 2024[18] Market Strategy - The company plans to focus on accelerating market access and promotion of aortic and peripheral interventional products in Europe, Latin America, and Asia-Pacific in 2025[9] - Six products are expected to obtain regulatory approval in 2025, with several others anticipated to complete registration or clinical trials[9] Shareholder Actions - The company repurchased a total of 1,952,089 shares, accounting for 1.58% of the total share capital, with a total expenditure of RMB 191,549,546.27[12][13] - The highest repurchase price during the first phase was RMB 103.96 per share, while the second phase saw a peak of RMB 119.82 per share[13] Accounting Changes - The company plans to implement new accounting standards starting in 2025, which may affect the financial statements[22]

Group 1 - The core point of the article indicates that the company reported a revenue of 332 million yuan for the first quarter of 2025, representing a year-on-year decline of 7.23% [1] - The net profit for the same period was 130 million yuan, which reflects a year-on-year decrease of 29.66% [1]

Core Viewpoint - The company, Shanghai MicroPort MedBot (Group) Co., Ltd., will participate in the 2024 annual performance briefing for the medical device industry organized by the Shanghai Stock Exchange, aiming to provide investors with insights into its 2024 operational results and financial status [2][3]. Group 1: Event Details - The investor briefing will be held on April 25, 2025, from 15:00 to 17:00, in an online interactive format via the Shanghai Stock Exchange Roadshow Center [6][7]. - Investors can submit questions in advance until April 24, 2025, at 16:00, either through the Roadshow Center or via the company's email [5][6]. Group 2: Participants - Key participants in the briefing include Dr. Zhu Qing (CEO), Mr. Ye Xiaojie (Independent Director), Mr. Liu Hao (Vice President of Treatment Solutions), Mr. Qiu Genyong (Vice President and Board Secretary), and Ms. Li Chunfang (Senior Financial Director) [4]. Group 3: Contact Information - For inquiries, investors can contact the Board Office at 021-38139300 or via email at irm@endovastec.com [8].

证券代码：688016 证券简称：心脉医疗 公告编号：2025-021 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果 及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2025 年 4 月 25 日（星期五）下午 15:00-17:00 上海微创心脉医疗科技（集团）股份有限公司 关于参加 2024 年度科创板医疗器械行业集体业绩说 明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海微创心脉医疗科技（集团）股份有限公司（以下简称"公司"）已于 2025 年 3 月 29 日在上海证券交易所网站（www.sse.com.cn）披露公司 2024 年年 度报告，为便于广大投资者更全面深入地了解公司 2024 年年度经营成果、财务 状况、发展理念，公司参与了由上海证券交易所主办的 2024 年度科创板医疗器 械行业集体业绩说明会，此次活动将采用网络文字互动的方式举行， ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly on innovative drugs and their internationalization process, while suggesting a focus on blood products and scientific instruments in the short term [4][18]. Core Insights - The pharmaceutical sector has shown stable stock performance, with significant approvals for innovative drugs such as the IL-21/IL-23 dual antibody by Kangfang Biopharma and the successful phase 3 clinical trial results for Eli Lilly's orforglipron [1][2][18]. - The report emphasizes the resilience and growth potential of the pharmaceutical sector amidst changing external tariff environments, highlighting low geopolitical risks for innovative drugs and opportunities for domestic replacements in blood products and medical devices [4][18]. - The report suggests a continuous focus on innovative and semi-innovative drug companies, as well as potential recovery in the performance of generic drugs, chain pharmacies, and traditional Chinese medicine post-Q1 reports [4][20]. Summary by Sections Pharmaceutical Sector - Kangfang Biopharma's IL-21/IL-23 dual antibody has been approved for moderate to severe plaque psoriasis, marking a significant milestone as the first domestic drug of its kind [19]. - The approval of AstraZeneca's capivasertib for second-line breast cancer treatment further highlights the growing number of innovative drugs being approved in China [23][25]. - The report anticipates a surge in licensing transactions as Chinese innovative drug assets mature, leading to more predictable performance for pharmaceutical companies [2][25]. Biological Products - Eli Lilly's orforglipron has successfully completed phase 3 clinical trials, demonstrating superior A1C reduction compared to placebo, which positions it as a leading oral GLP-1 receptor agonist [26][29]. - The report encourages monitoring the progress of domestic GLP-1 small molecules, which are showing promising clinical results [33][34]. Medical Devices - Domestic companies are making significant strides in innovative research and development, with products like the LiqMagic peripheral vascular shockwave treatment system gaining traction in clinical applications [35][36]. - The report notes that the innovative technology in vascular treatment is expected to enhance patient outcomes and reduce procedural risks [35][36]. Investment Recommendations - The report recommends focusing on innovative and semi-innovative drug companies such as Kelun-Biotech, Kangfang Biopharma, and Huadong Medicine, as well as blood products and scientific instruments for potential domestic replacements [5][20]. - It also suggests paying attention to the recovery of generic drugs, chain pharmacies, and traditional Chinese medicine as the market stabilizes post-Q1 [4][20].

证券代码：688016 证券简称：心脉医疗 公告编号：2025-020 上海微创心脉医疗科技（集团）股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年4月18日 （二）股东大会召开的地点：上海市浦东新区康新公路3399弄25号楼9层公司会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： 1、公司在任董事7人，出席7人； 2、公司在任监事3人，出席3人； 3、公司董事会秘书出席了本次会议；公司部分高管列席了本次会议，见证律师见证了本次会议。 二、议案审议情况 （一）非累积投票议案 1、议案名称：关于公司《2024年年度报告》及其摘要的议案 ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会采用现场投票和网络投票相结合的方式召开，会议由董事会召集，董事长Jonathan Chen先 生主持，本 ...

证券代码：688016 证券简称：心脉医疗 公告编号：2025-020 上海微创心脉医疗科技（集团）股份有限公司 2024 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （二） 股东大会召开的地点：上海市浦东新区康新公路 3399 弄 25 号楼 9 层公 司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 157 | | --- | --- | | 普通股股东人数 | 157 | | 2、出席会议的股东所持有的表决权数量 | 52,339,749 | | 普通股股东所持有表决权数量 | 52,339,749 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 43.1579 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 43.1579 | （四） 表决方式是否符合《公司法》 ...